Nat Biotechnol:光控基因编辑CRISPR/Cas9系统问世

2015-06-18 佚名 不详

日本的科学家们已经开发出一种光活化的Cas9核酸酶来控制CRISPR诱导的基因编辑,一个“开关”即可激活。这个光激活的Cas9核酸酶可以为研究者在RNA诱导的核酸酶研究上提供更大的空间和时间的控制。这篇研究在线发表在最新的Nature Biotechnology中。 来自加州大学的干细胞生物学家Paul Knoepfler评论这项研究时表示:“这是一种非常有效的新系统,通过光精确地控制基因编

日本的科学家们已经开发出一种光活化的Cas9核酸酶来控制CRISPR诱导的基因编辑,一个“开关”即可激活。这个光激活的Cas9核酸酶可以为研究者在RNA诱导的核酸酶研究上提供更大的空间和时间的控制。这篇研究在线发表在最新的Nature Biotechnology中。

来自加州大学的干细胞生物学家Paul Knoepfler评论这项研究时表示:“这是一种非常有效的新系统,通过光精确地控制基因编辑。任何先进的技术,能够增加转基因的精确度和控制都是一个重要的进步。我们做的就是其中之一。”

最近日本东京大学的化学家Moritoshi Sato和他的同事开发一种光学开关蛋白,称为“Magnets”(磁铁蛋白)。当光激活时,这些蛋白会因为静电相互作用而聚到一起。该团队还利用光活化技术,开发出光激活CRISPR转录体系,调节目标特定基因的表达。现在, Moritoshi Sato的研究小组更进一步,利用其磁蛋白创造了光活化Cas9核酸酶(photoactivatable Cas9 nuclease,paCas9)。“现有的Cas9酶是不能够修改组织一小群细胞的基因,例如脑内的神经元,”Sato说道,“此外,现有Cas9经常出现脱靶效应,归因于其不可控制的核酸酶活性。我们一直热衷于开发强大的工具,使得能在空间和时间上控制基因组编辑。”

研究人员先将Cas9蛋白分成两个无活性的片段。然后他们在各个片段中加上一个磁体蛋白质。当用蓝光照射,磁蛋白聚到一起,分开的Cas9片段合并重组,激活RNA引导的核酸酶活性。重要的是,该过程是可逆的:当光被关闭时,paCas9核酸酶再次分裂开,核酸酶活性被暂停。

CRISPR/Cas9基因编辑技术业内领先实验室Feng Zhang实验组的 Fei Ann Ran评价这个新研究是“利用拆分Cas9结构来允许光激活的基因编辑”,“这是用Cas9的结构知识来工程改造扩展它功能的一个很好的示范,并增加了CRISPR/Cas9系统的通用性”。

Knoepfler表示,使用磁铁蛋白方式的光激活系统运作良好,而且一些研究人员可能会发现它在特定的应用上的角色。例如,特定的发育学研究中,通过精确导向的光束,激活超精密的某种发育基因的编辑,算是一种非常优雅的方式。他补充说,目前还不清楚该系统能否有效地减少CRISPR的脱靶效应,不过任何能够减少基因编辑组分激活时间的技术都可谓是增加了CRISPR的效率。

Sato的研究小组现在计划扩大可以激活paCas9核酸酶的光谱。开发配合不同颜色光的新型光开关蛋白质将是一个关键因素。

原始出处:

Nihongaki Y, Kawano F, Nakajima T, Sato M.Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol. 2015 Jun 15. doi: 10.1038/nbt.3245

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2016-02-03 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-09-10 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-09-10 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2016-03-12 shock_melon
  7. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-20 yuandd
  9. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=105978, encodeId=9b771059e83f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:40:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880696, encodeId=da58188069689, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 03 07:27:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927626, encodeId=2712192e6260b, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Thu Sep 10 17:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917164, encodeId=5c9e191e1641a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 00:27:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950095, encodeId=fd291950095b3, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Feb 13 21:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652137, encodeId=78bc165213e31, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 12 21:27:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29224, encodeId=78e62922492, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275836, encodeId=aed012e5836a5, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341221, encodeId=3fd61341221e8, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364985, encodeId=fd6b1364985ac, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-20 respect

相关资讯

CRISPR技术剪掉HIV病毒基因,根治艾滋病

艾滋病病毒是一种高效且多变的逆转录病毒。一旦病毒将其DNA插入宿主细胞的基因组,它即拥有很长的潜伏期,可以保持休眠和隐匿状态达数年之久。 虽然医生可以通过多种不同的抗逆转录病毒药物搭配使用的鸡尾酒疗法来控制病毒,但若停止治疗,病毒即可恢复活力。 为了使潜伏中的艾滋病病毒失活,马萨诸塞大学医学院(University of Massachusetts Medical School

Nature:再掀学术伦理之争!中国科学家瞄准人类胚胎基因改造

中国科学家走在世界的第一位,首次报道成果对人类胚胎的基因进行改造。该项研究结果在线发表在最新一期 Protein & Cell 杂志上。这一消息正式确认了科学界关于对人类胚胎基因研究工作正在开展的谣言,而后者因伦理问题在上个月引起了激烈的讨论。 在这项由中山大学基因功能学教授Jun-jiu Huang所主持的研究中,研究人员利用来自当地生殖医疗机构“不能存活”的胚

全新基因编辑技术引发研究领域巨变

美国旧金山格莱斯顿研究所遗传学家Bruce Conklin一直试图找到DNA变异如何影响不同的人类疾病,但使用的工具有些笨重。当他研究来自病人的细胞时,很难知道哪个序列对疾病来说很重要,哪些只是背景噪音。同时,将突变植入细胞是一项昂贵且费力的工作。 2012年,他通过阅读了解到一项最新发表的、被称为CRISPR的技术。它能使研究人员快速改变几乎任何生物体的DNA,包括人类。此后不

PNAS:用CRISPR解决世界性难题

近年来致病菌的抗生素抗性越演越烈,这已经成为了一个世界性的难题。科学家们日前在CRISPR技术的基础上,开发了一个双噬菌体系统,能够使耐药菌敏感化,并且有选择的杀死它们。这项研究发表在五月十八日的美国国家科学院院刊PNAS杂志上。传统的噬菌体疗法是用一种或多种噬菌体去感染和裂解相应的细菌菌株。不过,把噬菌体递送到被感染的组织还存在一定的困难。Tel Aviv大学Udi Qimron等人开发的这种改

CRISPR、RNAi、TALEN一张图教你做出正确选择

研究基因功能最常见的方法是,减少或者阻断基因表达,然后进行表型分析。十多年来,RNAi一直是这一领域的王者,然而新兴技术的涌现(尤其是CRISPR技术)正在逐渐瓦解RNAi的统治地位。日新月异的技术发展为生物学研究提供了越来越大的助力,也给研究者们带来了一个有些纠结的问题,“到底应该选择那一种技术呢”。  1998年Andrew Fire 和Craig Mello两位科学家首次

Nat Biotech:科学家成功能将CRISPR/Cas9效率提高19倍

  CRISPR/Cas系统可以构建出多个基因精确突变的小鼠,但其效率低下阻碍了生成足够数量的转基因小鼠来建立人类疾病模型。通过添加一种抗癌药物Scr7到遗传编辑的受精卵中,Whitehead研究所的科学家将CRISPR/Cas的效率显着提高了19倍。这一重要的成果发表在本周的《自然生物技术》(Nature Biotechnology)杂志上。 CRISPR- Cas系统是通过在